BR9609743A - Formulação reconstituída estável método para a preparação de uma formulação artigo manufaturado e uso da formação - Google Patents

Formulação reconstituída estável método para a preparação de uma formulação artigo manufaturado e uso da formação

Info

Publication number
BR9609743A
BR9609743A BR9609743A BR9609743A BR9609743A BR 9609743 A BR9609743 A BR 9609743A BR 9609743 A BR9609743 A BR 9609743A BR 9609743 A BR9609743 A BR 9609743A BR 9609743 A BR9609743 A BR 9609743A
Authority
BR
Brazil
Prior art keywords
formulation
formation
preparation
manufactured article
reconstituted
Prior art date
Application number
BR9609743A
Other languages
English (en)
Inventor
James Andya
Jeffrey L Cleland
Xanthe M Lam
Chung C Hsu
Steven J Shire
David E Overcashier
Janet Yu-Feng Yang
Sylvia Sau-Yan Wu
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27056058&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9609743(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/615,369 external-priority patent/US6267958B1/en
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of BR9609743A publication Critical patent/BR9609743A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Reproductive Health (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
BR9609743A 1995-07-27 1996-07-23 Formulação reconstituída estável método para a preparação de uma formulação artigo manufaturado e uso da formação BR9609743A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US50801495A 1995-07-27 1995-07-27
US08/615,369 US6267958B1 (en) 1995-07-27 1996-03-14 Protein formulation
PCT/US1996/012251 WO1997004801A1 (en) 1995-07-27 1996-07-23 Stabile isotonic lyophilized protein formulation

Publications (1)

Publication Number Publication Date
BR9609743A true BR9609743A (pt) 1999-03-02

Family

ID=27056058

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9609743A BR9609743A (pt) 1995-07-27 1996-07-23 Formulação reconstituída estável método para a preparação de uma formulação artigo manufaturado e uso da formação

Country Status (18)

Country Link
EP (3) EP1516628B1 (pt)
JP (7) JPH11510170A (pt)
CN (3) CN102416176A (pt)
AR (2) AR003969A1 (pt)
AU (1) AU716785B2 (pt)
BR (1) BR9609743A (pt)
CA (2) CA2745743A1 (pt)
DK (2) DK2275119T3 (pt)
ES (2) ES2434840T3 (pt)
HK (2) HK1117075A1 (pt)
IL (1) IL122910A (pt)
MX (1) MX9800684A (pt)
NO (2) NO323557B1 (pt)
NZ (2) NZ313503A (pt)
PT (2) PT2275119E (pt)
RU (2) RU2497500C2 (pt)
SI (2) SI2275119T1 (pt)
WO (1) WO1997004801A1 (pt)

Families Citing this family (337)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL122910A (en) * 1995-07-27 2002-05-23 Genentech Inc Stable isotonic protein formulation that has undergone lyophilization
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
GB9610992D0 (en) * 1996-05-24 1996-07-31 Glaxo Group Ltd Concentrated antibody preparation
EP0852951A1 (de) * 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
US6991790B1 (en) 1997-06-13 2006-01-31 Genentech, Inc. Antibody formulation
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
ES2190087T3 (es) * 1997-06-13 2003-07-16 Genentech Inc Formulacion estabilizada de un anticuerpo.
ATE297761T1 (de) * 1998-03-26 2005-07-15 Schering Corp Zubereitungen zur stabilisierung von peg- interferon alpha konjugaten
EP2311436A1 (en) 1998-04-27 2011-04-20 Altus Pharmaceuticals Inc. Stabilized protein crystals, formulations containing them and methods of making them
AU760048B2 (en) * 1998-05-06 2003-05-08 Genentech Inc. Protein purification by ion exchange chromatography
US20030166525A1 (en) 1998-07-23 2003-09-04 Hoffmann James Arthur FSH Formulation
CN1053590C (zh) * 1998-10-19 2000-06-21 卫生部长春生物制品研究所 冻干甲型肝炎减毒活疫苗及其保护剂
RS51237B (sr) 1998-10-23 2010-12-31 Kirin Amgen Inc. Trombopoietska jedinjenja
PT1157041E (pt) 1999-03-01 2005-10-31 Genentech Inc Anticorpos para terapia e diagnostico de cancro
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
JP4557098B2 (ja) * 1999-03-31 2010-10-06 味の素株式会社 安定な６−アミジノ−２−ナフチル４−グアニジノベンゾエート酸付加塩製剤ならびにその製造方法
DE60034445T2 (de) * 1999-05-31 2008-01-03 Mitsubishi Chemical Corp. Gefriergetrocknete hgf-präparationen
AU5812800A (en) * 1999-06-12 2001-01-02 Stefan Barth Pharmaceutical preparation
IL146954A0 (en) 1999-06-25 2002-08-14 Genentech Inc HUMANIZED ANTI-ErbB2 ANTIBODIES AND TREATMENT WITH ANTI-ErbB2 ANTIBODIES
EP1191944A2 (en) 1999-06-25 2002-04-03 Genentech, Inc. METHODS OF TREATMENT USING ANTI-ErbB ANTIBODY-MAYTANSINOID CONJUGATES
EP1064934A1 (en) * 1999-06-30 2001-01-03 Applied Research Systems ARS Holding N.V. GRF-containing lyophilized pharmaceutical composition
DK1210115T3 (da) 1999-08-27 2009-11-30 Genentech Inc Doseringer til behandling med anti-ErB2-antistoffer
JP4776843B2 (ja) 1999-10-01 2011-09-21 イムノゲン インコーポレーティッド 免疫複合体及び化学療法剤を用いる癌治療用組成物及び方法
HU227347B1 (en) * 1999-10-04 2011-04-28 Novartis Vaccines & Diagnostic Stabilized liquid polypeptide-containing pharmaceutical compositions
ATE400296T1 (de) * 1999-12-02 2008-07-15 Novartis Vaccines & Diagnostic Zusammensetzungen und methoden zur stabilisierung von biologischen molekülen nach lyophilisierung
CA2396503A1 (en) 1999-12-14 2001-06-21 Jeffrey W. Steaffens Stabilizing diluent for polypeptides and antigens
GB9930882D0 (en) * 1999-12-30 2000-02-23 Nps Allelix Corp GLP-2 formulations
US7097840B2 (en) 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
US6632979B2 (en) 2000-03-16 2003-10-14 Genentech, Inc. Rodent HER2 tumor model
DK1282443T3 (da) 2000-05-19 2010-01-04 Genentech Inc Gendetektionsassay til at forbedre sandsynligheden for et effektivt respons på en ErbB-antagonist cancerterapi
AU2001268363B2 (en) 2000-06-20 2006-08-17 Biogen Idec Inc. Treatment of B cell associated diseases
DK1314437T3 (da) 2000-08-11 2014-07-14 Chugai Pharmaceutical Co Ltd Stabiliserede antistofindeholdende præparater
US20020058029A1 (en) 2000-09-18 2002-05-16 Nabil Hanna Combination therapy for treatment of autoimmune diseases using B cell depleting/immunoregulatory antibody combination
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
IL155002A0 (en) * 2000-10-12 2003-10-31 Genentech Inc Reduced-viscosity concentrated protein formulations
CA2426952C (en) 2000-11-02 2012-06-26 Sloan-Kettering Institute For Cancer Research Small molecule compositions for binding to hsp90
EP1372724A2 (en) 2001-01-31 2004-01-02 Idec Pharmaceuticals Corporation Use of immunoregulatory antibodies in the treatment of neoplastic disorders
US20020159996A1 (en) 2001-01-31 2002-10-31 Kandasamy Hariharan Use of CD23 antagonists for the treatment of neoplastic disorders
JP2005503999A (ja) 2001-01-31 2005-02-10 アイデック ファーマスーティカルズ コーポレイション 腫瘍性疾患の治療のためのｃｄ２３拮抗剤の使用
US7825094B2 (en) 2001-05-23 2010-11-02 Sloan-Kettering Institute For Cancer Research Method of treatment for cancers associated with elevated HER 2 levels
GB0113179D0 (en) * 2001-05-31 2001-07-25 Novartis Ag Organic compounds
CA2868614A1 (en) 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
DE10133394A1 (de) * 2001-07-13 2003-01-30 Merck Patent Gmbh Flüssige Formulierung enthaltend Cetuximab
ATE454137T1 (de) * 2001-07-25 2010-01-15 Facet Biotech Corp Stabile lyophilisierte pharmazeutische formulierung des igg-antikörpers daclizumab
CA2466034C (en) * 2001-11-08 2012-12-18 Protein Design Labs, Inc. Stable aqueous pharmaceutical formulations of daclizumab antibodies
CN100415769C (zh) * 2002-02-07 2008-09-03 中国科学院过程工程研究所 寡聚或多聚亚基蛋白质分离纯化的方法
CN101721362B (zh) * 2002-02-14 2018-07-03 中外制药株式会社 包含抗体的溶液制剂
DE10211227A1 (de) * 2002-03-13 2003-10-02 Aventis Behring Gmbh Verfahren zur Rekonstitution von Iyophilisierten Proteinen
EP2289942B1 (en) 2002-04-10 2013-07-31 Genentech, Inc. Anti-HER2 antibody variants
JP2005532395A (ja) * 2002-07-02 2005-10-27 スミスクライン・ビーチャム・コーポレイション 新規な安定処方
MXPA05000403A (es) 2002-07-15 2005-07-22 Genentech Inc Metodos para identificar tumores que responden al tratamiento con anticuerpos contra erbb2.
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
PT1543038T (pt) 2002-09-11 2017-07-07 Genentech Inc Purificação de proteína
MY150740A (en) 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
US20050053598A1 (en) 2003-02-10 2005-03-10 Burke David J. Immunoglobulin formulation and method of preparation thereof
US20050142139A1 (en) * 2003-03-21 2005-06-30 Norbert Schulke CD4-IgG2 formulations
CA2518903C (en) 2003-04-02 2013-02-05 Ares Trading S.A. Liquid pharmaceutical formulations of fsh and lh together with a non-ionic surfactant
DK2335725T3 (en) * 2003-04-04 2017-01-23 Genentech Inc Highly concentrated antibody and protein formulations
AU2012200957B2 (en) * 2003-04-04 2014-10-23 Genentech, Inc. High concentration antibody and protein formulations
FR2853551B1 (fr) 2003-04-09 2006-08-04 Lab Francais Du Fractionnement Formulation stabilisante pour compositions d'immunoglobulines g sous forme liquide et sous forme lyophilisee
ES2322267T3 (es) 2003-04-09 2009-06-18 Genentech, Inc. Terapia de una enfermedad autoinmunologica en un paciente que presenta una respuesta inadecuada a un inhibidor de tnf-alfa.
MXPA05012259A (es) * 2003-05-14 2006-04-18 Immunogen Inc Composicion de farmaco conjugado.
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
KR20160014775A (ko) 2003-05-30 2016-02-11 제넨테크, 인크. 항-ｖｅｇｆ 항체를 사용한 치료
DK1631313T3 (en) 2003-06-05 2015-06-15 Genentech Inc Combination therapy for b cell disorders
PT1638595E (pt) 2003-06-20 2013-04-26 Ares Trading Sa Fsh liofilizada / formulações de hl
EP1660531A2 (en) 2003-08-05 2006-05-31 Novo Nordisk A/S Novel insulin derivatives
US7459021B2 (en) 2003-09-03 2008-12-02 Shmuel Bukshpan Methods and apparatus for rapid crystallization of biomolecules
US8277810B2 (en) 2003-11-04 2012-10-02 Novartis Vaccines & Diagnostics, Inc. Antagonist anti-CD40 antibodies
TR201809892T4 (tr) 2003-11-05 2018-07-23 Roche Glycart Ag Fc reseptörüne bağlanma afinitesi ve artırılmış efektör fonksiyonu bulunan antijen bağlayan moleküller.
DE10355251A1 (de) * 2003-11-26 2005-06-23 Merck Patent Gmbh Pharmazeutische Zubereitung enthaltend einen Antikörper gegen den EGF-Rezeptor
WO2005072772A1 (en) * 2004-01-30 2005-08-11 Suomen Punainen Risti Veripalvelu Pharmaceutical compositions
WO2005089503A2 (en) * 2004-03-19 2005-09-29 Progenics Pharmaceuticals, Inc. Cd4-igg2 formulations
US7319032B2 (en) 2004-04-22 2008-01-15 Medtox Non-sugar sweeteners for use in test devices
US7727962B2 (en) 2004-05-10 2010-06-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Powder comprising new compositions of oligosaccharides and methods for their preparation
US7723306B2 (en) 2004-05-10 2010-05-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Spray-dried powder comprising at least one 1,4 O-linked saccharose-derivative and methods for their preparation
US7611709B2 (en) 2004-05-10 2009-11-03 Boehringer Ingelheim Pharma Gmbh And Co. Kg 1,4 O-linked saccharose derivatives for stabilization of antibodies or antibody derivatives
DE102004022927A1 (de) * 2004-05-10 2005-12-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg 1,4 O-verknüpfte Saccharose-Derivate zur Stabilisierung von Antikörpern oder Antikörper-Derivaten
CA2567520A1 (en) 2004-06-01 2005-12-15 Genentech, Inc. Maytansinoid-antibody conjugates
WO2006014965A2 (en) * 2004-07-27 2006-02-09 Human Genome Sciences, Inc. Pharmaceutical formulation and process
US20060051347A1 (en) * 2004-09-09 2006-03-09 Winter Charles M Process for concentration of antibodies and therapeutic products thereof
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
EP3088004B1 (en) 2004-09-23 2018-03-28 Genentech, Inc. Cysteine engineered antibodies and conjugates
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
JP4993645B2 (ja) 2004-12-01 2012-08-08 ジェネンテック， インコーポレイテッド 抗体薬剤結合体および方法
MX2007006822A (es) * 2004-12-15 2007-07-24 Amgen Inc Formulaciones terapeuticas para el factor de crecimiento de queratinocitos.
CN101141981A (zh) 2005-01-21 2008-03-12 健泰科生物技术公司 Her抗体的固定剂量给药
CN1313161C (zh) * 2005-01-27 2007-05-02 北京大学临床肿瘤学院 结直肠癌放射免疫导向手术药物及其制备方法
US9403828B2 (en) 2005-02-01 2016-08-02 Sloan-Kettering Institute For Cancer Research Small-molecule Hsp90 inhibitors
US7834181B2 (en) 2005-02-01 2010-11-16 Slaon-Kettering Institute For Cancer Research Small-molecule Hsp90 inhibitors
ES2755976T3 (es) 2005-02-07 2020-04-24 Roche Glycart Ag Moléculas de unión a antígeno que se unen a EGFR, vectores que las codifican y usos de las mismas
CN103251946A (zh) 2005-02-23 2013-08-21 健泰科生物技术公司 使用her二聚化抑制剂在癌症患者中延长病情进展前时间或存活
CN101141975B (zh) * 2005-03-25 2012-05-23 瑞泽恩制药公司 Vegf拮抗剂制剂
CA2615122A1 (en) * 2005-08-03 2007-02-15 Immunogen, Inc. Immunoconjugate formulations
JP5373396B2 (ja) 2005-08-26 2013-12-18 ロシュ グリクアート アクチェンゲゼルシャフト 改変された細胞シグナル活性有する改変抗原結合分子
BRPI0618893A2 (pt) * 2005-11-22 2011-09-13 Wyeth Corp formulações de proteìna de fusão de imunoglobulina
KR101398713B1 (ko) 2005-12-20 2014-06-12 브리스톨-마이어스 스큅 컴퍼니 조성물 및 조성물의 제조 방법
AR058568A1 (es) 2005-12-20 2008-02-13 Bristol Myers Squibb Co Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo
US9309316B2 (en) 2005-12-20 2016-04-12 Bristol-Myers Squibb Company Stable subcutaneous protein formulations and uses thereof
SG153832A1 (en) * 2005-12-20 2009-07-29 Bristol Myers Squibb Co Stable protein formulations
PL1969004T3 (pl) 2005-12-28 2012-01-31 Novo Nordisk As Kompozycje zawierające acylowaną insulinę i cynk oraz sposób wytwarzania tych kompozycji
EP1986612B1 (en) * 2006-02-07 2012-09-12 Shire Human Genetic Therapies, Inc. Stabilized composition of glucocerebrosidase
EP1989231B1 (en) 2006-03-21 2015-05-20 Genentech, Inc. Combinatorial therapy involving alpha5beta1 antagonists
EP2004221A2 (en) 2006-03-23 2008-12-24 Novartis Pharma AG Anti-tumor cell antigen antibody therapeutics
CA2647029A1 (en) 2006-04-05 2007-10-18 Abbott Biotechnology Ltd. Antibody purification
EP2010214A4 (en) 2006-04-10 2010-06-16 Abbott Biotech Ltd USES AND COMPOSITIONS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS
JO3324B1 (ar) * 2006-04-21 2019-03-13 Amgen Inc مركبات علاجية مجففة بالتبريد تتعلق بالعصارة الهضمية
AU2011265555B2 (en) * 2006-04-21 2016-03-10 Amgen Inc. Lyophilized therapeutic peptibody formulations
KR101406811B1 (ko) 2006-06-16 2014-06-12 리제너론 파마슈티칼스 인코포레이티드 유리체내 투여에 적당한 ｖｅｇｆ 길항제 제형
AR062223A1 (es) 2006-08-09 2008-10-22 Glycart Biotechnology Ag Moleculas de adhesion al antigeno que se adhieren a egfr, vectores que los codifican, y sus usos de estas
CN101199845B (zh) * 2006-12-14 2012-05-23 上海国健生物技术研究院 一种稳定的抗IgE人源化单抗制剂
CN101199483B (zh) * 2006-12-14 2011-01-26 上海中信国健药业股份有限公司 一种稳定的抗her2人源化抗体制剂
CA2674608A1 (en) * 2007-01-09 2008-07-17 Wyeth Anti-il-13 antibody formulations and uses thereof
BRPI0806605A2 (pt) 2007-01-16 2011-09-06 Abbott Lab métodos para tratar psorìase
MX2009008692A (es) * 2007-02-16 2009-08-21 Wyeth Corp Uso de sacarosa para suprimir la agregacion de proteina inducida por manitol.
PL2132573T3 (pl) 2007-03-02 2014-09-30 Genentech Inc Prognozowanie odpowiedzi na inhibitor dimeryzacji HER oparte na niskiej ekspresji HER3
BRPI0809209A2 (pt) 2007-03-29 2014-09-02 Abbott Lab Anticorpos il-12 anti-humanos cristalinos
EP2171451A4 (en) 2007-06-11 2011-12-07 Abbott Biotech Ltd METHOD FOR TREATING JUVENILIAN IDIOPATHIC ARTHRITIS
ES2744384T3 (es) 2007-06-13 2020-02-24 Novo Nordisk As Formulación farmacéutica que comprende un derivado de insulina
US20110152345A1 (en) 2007-08-24 2011-06-23 Oncotherapy Science, Inc. Ebi3, dlx5, nptx1 and cdkn3 for target genes of lung cancer therapy and diagnosis
JP2010536844A (ja) 2007-08-24 2010-12-02 オンコセラピー・サイエンス株式会社 癌の治療標的及び診断マーカーとしてのｄｋｋ１癌遺伝子
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
KR20090056543A (ko) * 2007-11-30 2009-06-03 주식회사 녹십자 Ｂ형 간염 바이러스(ｈｂｖ) 중화 인간 항체를 포함하는약학적 제제
US11197916B2 (en) 2007-12-28 2021-12-14 Takeda Pharmaceutical Company Limited Lyophilized recombinant VWF formulations
MX2010007150A (es) 2007-12-28 2010-09-03 Baxter Int Formulaciones del factor de von-willebrand recombinante.
US8574577B2 (en) 2008-01-03 2013-11-05 The Scripps Research Institute VEGF antibodies comprising modular recognition domains
US8557242B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute ERBB2 antibodies comprising modular recognition domains
US8557243B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute EFGR antibodies comprising modular recognition domains
NZ586701A (en) 2008-01-03 2013-07-26 Scripps Research Inst Antibody targeting through a modular recognition domain (MRD) wherein the MRD targets angiopoietin-2 (ANG-2)
US8454960B2 (en) 2008-01-03 2013-06-04 The Scripps Research Institute Multispecific antibody targeting and multivalency through modular recognition domains
EP2085095B1 (en) 2008-01-17 2012-03-07 Philogen S.p.A. Combination of an anti-EDb fibronectin antibody-IL-2 fusion protein, and a molecule binding to B cells, B cell progenitors and/or their cancerous counterpart
AR070141A1 (es) 2008-01-23 2010-03-17 Glenmark Pharmaceuticals Sa Anticuerpos humanizados especificos para el factor von willebrand
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
BRPI0822447A2 (pt) 2008-03-14 2015-06-16 Biocon Ltd Anticorpo monoclonal e método do mesmo
CY1112212T1 (el) * 2008-04-24 2015-12-09 Immatics Biotechnologies Gmbh Νεα σκευασματα πεπτιδιων που σχετιζονται με ογκους τα οποια συνδεονται σε μορια του αντιγονου ανθρωπινων λευκοκυτταρων (hla) ταξης i ή ii για εμβολια
SI2113253T1 (sl) * 2008-04-30 2010-06-30 Immatics Biotechnologies Gmbh Nove formulacije s tumorjem povezanih peptidov ki se vežejo na molekule humanega levkocitnega antigena HLA razreda I ali II za cepiva
US8093018B2 (en) 2008-05-20 2012-01-10 Otsuka Pharmaceutical Co., Ltd. Antibody identifying an antigen-bound antibody and an antigen-unbound antibody, and method for preparing the same
CA2727915C (en) 2008-07-15 2016-04-26 Genentech, Inc. Anthracycline derivative conjugates, process for their preparation and their use as antitumor compounds
TW201438738A (zh) 2008-09-16 2014-10-16 Genentech Inc 治療進展型多發性硬化症之方法
TWI508735B (zh) 2008-10-21 2015-11-21 巴克斯特國際公司 凍乾的重組ｖｗｆ調配物
AU2009333791B2 (en) * 2008-10-29 2013-04-04 Ablynx N.V. Formulations of single domain antigen binding molecules
KR20110079693A (ko) 2008-10-29 2011-07-07 와이어쓰 엘엘씨 단일 도메인 항원 결합 분자의 정제 방법
KR20110085985A (ko) 2008-10-30 2011-07-27 노보 노르디스크 에이/에스 하루 한번 주사 빈도보다 적은 인슐린 주사를 사용한 진성 당뇨병의 치료
BRPI0916138A2 (pt) 2008-11-22 2015-11-17 Genentech Inc "método de tratamento de um sujeito diagnosticado com câncer de mama localmente, kit para tratar câncer de mama metastático em um sujeito humano, uso de um anticorpo antivegf na fabricação de um medicamento para tratar câncer de mama localmente recidivado ou metastático em um sujeito e anticorpo anti-vegf para uso em um método de tratamento de câncer de mama localmente recidivado ou metastático em um sujeito"
EP2196476A1 (en) 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
FR2940617B1 (fr) * 2008-12-30 2012-04-20 Fractionnement Et Des Biotechonologies Lab Franc Composition d'immunoglobulines g
JP2012519706A (ja) 2009-03-06 2012-08-30 ジェネンテック， インコーポレイテッド 抗体製剤
SG174515A1 (en) 2009-03-25 2011-10-28 Genentech Inc NOVEL ANTI-a5ß1 ANTIBODIES AND USES THEREOF
CN102325549A (zh) 2009-03-31 2012-01-18 罗氏格黎卡特股份公司 用人源化抗-EGFR IgG1抗体和伊立替康治疗癌症
WO2010114859A1 (en) 2009-04-01 2010-10-07 Genentech, Inc. Treatment of insulin-resistant disorders
WO2010146059A2 (en) 2009-06-16 2010-12-23 F. Hoffmann-La Roche Ag Biomarkers for igf-1r inhibitor therapy
CN109172813B (zh) 2009-07-28 2022-09-02 武田药品工业株式会社 用于治疗戈谢病的组合物和方法
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
WO2011022264A1 (en) 2009-08-15 2011-02-24 Genentech, Inc. Anti-angiogenesis therapy for the treatment of previously treated breast cancer
US8470980B2 (en) 2009-09-09 2013-06-25 Centrose, Llc Extracellular targeted drug conjugates
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
ES2604103T3 (es) 2009-10-01 2017-03-03 F. Hoffmann-La Roche Ag Filtración final de una preparación de inmunoglobulina en múltiples pasos
EP3721904B1 (en) * 2009-11-20 2021-10-13 Biocon Limited Formulations of t1h antibody
RU2580038C2 (ru) 2009-12-04 2016-04-10 Дженентек, Инк. Мультиспецифические антитела, аналоги антител, композиции и способы
US9511122B2 (en) 2009-12-15 2016-12-06 Ascendis Pharma Growth Disorders Division A/S Dry growth hormone composition transiently linked to a polymer carrier
AU2010338305A1 (en) * 2009-12-29 2012-05-24 F. Hoffmann-La Roche Ag Antibody formulation
AR080428A1 (es) 2010-01-20 2012-04-11 Chugai Pharmaceutical Co Ltd Formulaciones liquidas estabilizadas contentivas de anticuerpos
WO2011101328A2 (en) 2010-02-18 2011-08-25 Roche Glycart Ag Treatment with a humanized igg class anti egfr antibody and an antibody against insulin like growth factor 1 receptor
US9795659B2 (en) 2010-02-19 2017-10-24 Cadila Pharmaceuticals, Ltd. Pharmaceutical composition of killed cells with substantially retained immunogenicity
EP3696194A1 (en) 2010-02-23 2020-08-19 F. Hoffmann-La Roche AG Anti-angiogenesis therapy for the treatment of ovarian cancer
NZ602115A (en) 2010-03-01 2014-12-24 Bayer Healthcare Llc Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
AU2011223805B2 (en) 2010-03-01 2015-10-29 Cytodyn Inc. Concentrated protein formulations and uses thereof
CN102892409B (zh) 2010-03-31 2015-12-09 稳定性科技有限公司 用于保存铝盐佐剂和铝盐-佐剂化疫苗的方法
HUE026885T2 (en) 2010-03-31 2016-08-29 Stabilitech Ltd Stabilize virus fragments
GB2490644A (en) 2010-03-31 2012-11-07 Stabilitech Ltd Excipients for stabilising viral particles, polypeptides or biological material
SG10201502398RA (en) * 2010-04-27 2015-05-28 Scil Technology Gmbh Stable MIA/CD-RAP formulations
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
WO2011153243A2 (en) 2010-06-02 2011-12-08 Genentech, Inc. Anti-angiogenesis therapy for treating gastric cancer
EP4008313A1 (en) * 2010-06-24 2022-06-08 F. Hoffmann-La Roche AG Compositions and methods for stablizing protein-containing formulations
AU2011274363A1 (en) * 2010-07-02 2013-01-24 Medimmune, Llc Antibody formulations
US20120100166A1 (en) 2010-07-15 2012-04-26 Zyngenia, Inc. Ang-2 Binding Complexes and Uses Thereof
EP2596128B1 (en) 2010-07-22 2015-04-22 President and Fellows of Harvard College Multiple input biologic classifier circuits for cells
CN103261225A (zh) 2010-07-23 2013-08-21 波士顿大学董事会 作为用于抑制病理性血管生成和肿瘤细胞侵袭力的治疗剂以及用于分子成像和靶向递送的抗DEspR抑制剂
CN106267189B (zh) * 2010-10-06 2021-02-26 瑞泽恩制药公司 含有抗白介素-4受体(il-4r)的抗体的稳定制剂
JP6049625B2 (ja) 2010-10-27 2016-12-21 ノヴォ ノルディスク アー／エス 様々な注射間隔を用いて施されるインスリン注射を使用する、真性糖尿病の治療
AR083847A1 (es) 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
AU2011336413B2 (en) 2010-12-02 2015-01-22 Oncolytics Biotech Inc. Liquid viral formulations
TW201233803A (en) 2010-12-02 2012-08-16 Oncolytics Biotech Inc Lyophilized viral formulations
US20140162317A1 (en) 2010-12-21 2014-06-12 Roberto Falkenstein Isoform entriched antibody preparation and method for obtaining it
CN102028661B (zh) * 2010-12-31 2012-05-23 山东新时代药业有限公司 聚乙二醇化重组人粒细胞集落刺激因子冻干粉针剂及其制备方法
KR20210030510A (ko) 2011-01-13 2021-03-17 리제너론 파아마슈티컬스, 인크. 혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도
KR20190116563A (ko) 2011-03-31 2019-10-14 머크 샤프 앤드 돔 코포레이션 인간 프로그램화된 사멸 수용체 pd-1에 대한 항체의 안정한 제제 및 관련된 치료
WO2012149197A2 (en) 2011-04-27 2012-11-01 Abbott Laboratories Methods for controlling the galactosylation profile of recombinantly-expressed proteins
WO2012162561A2 (en) 2011-05-24 2012-11-29 Zyngenia, Inc. Multivalent and monovalent multispecific complexes and their uses
TWI527590B (zh) 2011-06-17 2016-04-01 艾瑞斯貿易公司 Ｆｇｆ－１８之凍乾調配物
EP2735315B1 (en) 2011-07-19 2019-10-02 Chugai Seiyaku Kabushiki Kaisha Stable protein-containing preparation containing argininamide or valinamide
US20130022551A1 (en) 2011-07-22 2013-01-24 Trustees Of Boston University DEspR ANTAGONISTS AND AGONISTS AS THERAPEUTICS
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
GB201117233D0 (en) 2011-10-05 2011-11-16 Stabilitech Ltd Stabilisation of polypeptides
ES2736005T3 (es) 2011-10-14 2019-12-23 Hoffmann La Roche Pertuzumab, Trastuzumab, Docetaxel y Carboplatino para el tratamiento del cáncer de mama en fase precoz
PE20191242A1 (es) 2011-10-25 2019-09-16 Prothena Biosciences Ltd Formulaciones de anticuerpo y metodos
WO2013091903A1 (en) 2011-12-22 2013-06-27 Novo Nordisk A/S Anti-crac channel antibodies
WO2013096812A1 (en) 2011-12-23 2013-06-27 Genentech, Inc. Articles of manufacture and methods for co-administration of antibodies
CN102512384B (zh) * 2011-12-29 2014-11-26 嘉和生物药业有限公司 一种冻干剂型蛋白组合物及其制备方法
CA3056813A1 (en) 2012-03-13 2013-09-19 F. Hoffmann-La Roche Ag Combination therapy for the treatment of ovarian cancer
AU2013240261A1 (en) 2012-03-27 2014-09-18 Genentech, Inc. Diagnosis and treatments relating to HER3 inhibitors
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9334319B2 (en) 2012-04-20 2016-05-10 Abbvie Inc. Low acidic species compositions
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
US20140004131A1 (en) 2012-05-04 2014-01-02 Novartis Ag Antibody formulation
SI2849723T1 (sl) * 2012-05-18 2018-09-28 Genentech, Inc. Formulacije z visoko koncentracijo monoklonskih protiteles
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
US20140017318A1 (en) * 2012-07-10 2014-01-16 Kevin O'Connell Method to produce a medicinal product comprising a biologically active protein and the resulting product
KR20150038593A (ko) 2012-08-07 2015-04-08 제넨테크, 인크. 교모세포종의 치료를 위한 조합 요법
FR2994390B1 (fr) 2012-08-10 2014-08-15 Adocia Procede d'abaissement de la viscosite de solutions de proteines a concentration elevee
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
EP2890782A1 (en) 2012-09-02 2015-07-08 AbbVie Inc. Methods to control protein heterogeneity
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
WO2014045213A1 (en) 2012-09-18 2014-03-27 Adocia Stable pharmaceutical composition, comprising an aqueous solution of an antibody-derived therapeutically active protein
WO2014045081A1 (en) 2012-09-18 2014-03-27 Adocia Stable pharmaceutical composition, comprising an aqueous solution of an antibody-derived therapeutically active protein
JP6348115B2 (ja) 2012-10-26 2018-06-27 ザ ユニバーシティー オブ クイーンズランド がん療法のためのエンドサイトーシス阻害剤および抗体の使用
WO2014068029A1 (en) * 2012-10-31 2014-05-08 Takeda Gmbh Lyophilized formulation comprising gm-csf neutralizing compound
MX367748B (es) * 2012-12-21 2019-09-04 Glenmark Pharmaceuticals Sa Formulación de anticuerpo anti her2.
CA2905010A1 (en) 2013-03-12 2014-09-18 Abbvie Inc. Human antibodies that bind human tnf-alpha and methods of preparing the same
WO2014159579A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
BR112015023752B1 (pt) 2013-03-15 2023-11-14 Zyngenia, Inc. Domínio de reconhecimento modular (mrd), complexo compreendendo mrd e cetuximabe, usos do complexo para inibir a angiogênese e tratar câncer e composição farmacêutica compreendendo o dito complexo
WO2014140361A1 (en) * 2013-03-15 2014-09-18 Takeda Gmbh Formulation of an antibody and use thereof
JP2016519127A (ja) 2013-04-30 2016-06-30 ノヴォ ノルディスク アー／エス 新規投与レジメン
KR102276745B1 (ko) 2013-07-23 2021-07-14 바이오콘 리미티드 Cd6 결합 파트너의 용도 및 이에 기초한 방법
KR20240090993A (ko) 2013-08-30 2024-06-21 다케다 야쿠힌 고교 가부시키가이샤 류마티스성 관절염의 치료에서 또는 진통제로서 사용하기 위한 gm-csf 중화 항체
AR097762A1 (es) 2013-09-27 2016-04-13 Intervet Int Bv Formulaciones secas de vacunas que son estables a temperatura ambiente
EP3052640A2 (en) 2013-10-04 2016-08-10 AbbVie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
WO2015073884A2 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
EP3071237B1 (en) 2013-11-21 2024-06-26 Genmab A/S Antibody-drug conjugate lyophilised formulation
CN104707146B (zh) * 2013-12-16 2019-04-16 浙江海正药业股份有限公司 一种含有阿达木单抗的药物组合物
EP3104882B1 (en) 2014-02-14 2019-06-05 Centrose, Llc Extracellular targeted drug conjugates
CN103893135B (zh) * 2014-03-28 2017-01-11 中国医学科学院输血研究所 一种人血浆蛋白c的冻干稳定剂组合物及其用途
GB201406569D0 (en) 2014-04-11 2014-05-28 Stabilitech Ltd Vaccine compositions
EP3131584B1 (en) 2014-04-16 2022-01-12 Biocon Limited Stable protein formulations comprising a molar excess of sorbitol
ES2974895T3 (es) 2014-05-07 2024-07-02 Takeda Pharmaceuticals Co Formulación líquida que comprende un compuesto neutralizante de GM-CSF
EP3757134B1 (en) * 2014-05-28 2024-03-06 NoNO Inc. Chloride salt of tat-nr2b9c
PL3148581T3 (pl) 2014-05-30 2020-05-18 Henlix Biotech Co., Ltd. Przeciwciała przeciwko receptorowi naskórkowego czynnika wzrostu (EGFR)
US10562946B2 (en) 2014-06-20 2020-02-18 Genentech, Inc. Chagasin-based scaffold compositions, methods, and uses
US20170209582A1 (en) * 2014-06-26 2017-07-27 Amgen Inc. Protein formulations
WO2016019969A1 (en) 2014-08-08 2016-02-11 Ludwig-Maximilians-Universität München Subcutaneously administered bispecific antibodies for use in the treatment of cancer
EP3191527B1 (en) 2014-09-10 2020-01-15 F.Hoffmann-La Roche Ag Galactoengineered immunoglobulin 1 antibodies
BR112017010498A2 (pt) 2014-11-19 2017-12-26 Axon Neuroscience Se anticorpos tau humanizados em doença de alzheimer
EP3250927B1 (en) 2015-01-28 2020-02-19 H. Hoffnabb-La Roche Ag Gene expression markers and treatment of multiple sclerosis
US20180208658A1 (en) 2015-04-03 2018-07-26 Eureka Therapeutics, Inc. Constructs targeting afp peptide/mhc complexes and uses thereof
DK3287140T3 (da) 2015-04-21 2021-07-19 Beijing Staidson Medical Tech Co Ltd Nervevækstfaktorsammensætning og pulverinjektion
WO2016169453A1 (zh) 2015-04-21 2016-10-27 舒泰神（北京）生物制药股份有限公司 神经生长因子组合物及注射粉剂
CA2980189A1 (en) 2015-04-24 2016-10-27 Genentech, Inc. Multispecific antigen-binding proteins
BR112017024610A2 (pt) 2015-06-24 2018-07-31 F. Hoffmann-La Roche Ag anticorpos para receptor antitransferrina com afinidade especificada
WO2017031151A1 (en) 2015-08-18 2017-02-23 Regeneron Pharmaceuticals, Inc. Anti-pcsk9 inhibitory antibodies for treating patients with hyperlipidemia undergoing lipoprotein apheresis
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
MA43023A (fr) 2015-10-02 2018-08-08 Hoffmann La Roche Anticorps de récepteur de la transferrine humaine/anti-humaine cd20 bispécifique et leurs procédés d'utilisation
WO2017062682A2 (en) 2015-10-06 2017-04-13 Genentech, Inc. Method for treating multiple sclerosis
WO2017096031A1 (en) 2015-12-03 2017-06-08 Regeneron Pharmaceuticals, Inc. Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-vegf
US11229677B2 (en) 2016-01-12 2022-01-25 Intron Biotechnology, Inc. Antibacterial composition and a method of treating staphylococcal infections with the antibacterial composition
JP7085482B2 (ja) * 2016-01-12 2022-06-16 イントロン バイオテクノロジー，インコーポレイテッド スタフィロコッカス感染症のための凍結乾燥製剤を製造する方法
JP2019505520A (ja) 2016-01-13 2019-02-28 ゲンマブ エー／エス 抗体およびその薬物コンジュゲートの製剤
EP3423490A1 (en) 2016-03-01 2019-01-09 H. Hoffnabb-La Roche Ag Obinutuzumab and rituximab variants having reduced adcp
WO2017160835A1 (en) * 2016-03-14 2017-09-21 The Regents Of The University Of Michigan A surface tension mediated lyo-processing technique for preservation of biologics
IL262781B1 (en) 2016-05-10 2024-08-01 Genentech Inc Methods for reducing trisulfide bonds during recombinant production of polypeptides
KR20230162139A (ko) * 2016-06-01 2023-11-28 세르비에 아이피 유케이 리미티드 폴리알킬렌 옥시드-아스파라기나제의 제형, 및 그의 제조 및 사용 방법
GB201610198D0 (en) 2016-06-10 2016-07-27 Ucb Biopharma Sprl Anti-ige antibodies
EP3509616A1 (en) 2016-09-09 2019-07-17 H. Hoffnabb-La Roche Ag Selective peptide inhibitors of frizzled
ES2977137T3 (es) 2016-09-16 2024-08-19 Shanghai Henlius Biotech Inc Anticuerpos anti-PD-1
IL265665B2 (en) * 2016-10-07 2024-07-01 Regeneron Pharma A stable protein at room temperature that has been lyophilized
PT3529274T (pt) 2016-10-21 2024-06-21 Biocon Ltd Um anticorpo monoclonal e um método de utilização para o tratamento de lúpus
CA3044274A1 (en) 2016-11-21 2018-05-24 Obi Pharma, Inc. Conjugated biological molecules, pharmaceutical compositions and methods
CN110167582A (zh) 2016-12-15 2019-08-23 泰伦基国际有限公司 一种预防和治疗药物性肾损伤的方法
CN110121358A (zh) 2016-12-15 2019-08-13 泰伦基国际有限公司 一种预防和治疗肺纤维化的方法
WO2018107705A1 (zh) 2016-12-15 2018-06-21 深圳瑞健生命科学研究院有限公司 一种促进胰岛素分泌的方法
CN110114081A (zh) 2016-12-15 2019-08-09 泰伦基国际有限公司 一种改善心脏病变的方法
JP7531080B2 (ja) 2016-12-15 2024-08-09 タレンゲン インターナショナル リミテッド 骨粗鬆症を予防及び治療するための薬物およびその用途
WO2018108161A1 (zh) 2016-12-15 2018-06-21 深圳瑞健生命科学研究院有限公司 一种预防和治疗肥胖症的方法和药物
TW201822805A (zh) 2016-12-15 2018-07-01 深圳瑞健生命科學硏究院有限公司 一種預防和治療脂肪異常沉積導致的組織損傷的方法
CN110099926A (zh) 2016-12-28 2019-08-06 豪夫迈·罗氏有限公司 晚期her2表达性癌症的治疗
US11274157B2 (en) 2017-01-12 2022-03-15 Eureka Therapeutics, Inc. Constructs targeting histone H3 peptide/MHC complexes and uses thereof
MA47313B1 (fr) 2017-01-17 2020-12-31 Hoffmann La Roche Formulations sous-cutanées d'anticorps her2
WO2018158716A1 (en) 2017-03-02 2018-09-07 Cadila Healthcare Limited Novel protein drug conjugate formulation
KR20190096384A (ko) 2017-03-02 2019-08-19 제넨테크, 인크. Her2-양성 유방암 어쥬번트 치료
AU2018258049A1 (en) 2017-04-26 2019-12-12 Eureka Therapeutics, Inc. Constructs specifically recognizing glypican 3 and uses thereof
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
EP3618871A4 (en) 2017-05-02 2021-01-06 Merck Sharp & Dohme Corp. ANTI-LAG3 ANTIBODIES ETCO-FORMULATIONS ANTI-LAG3 ANTIBODIES AND ANTI-PD-1 ANTIBODIES
GB2562241B (en) 2017-05-08 2022-04-06 Stabilitech Biopharma Ltd Vaccine compositions
JP7263256B6 (ja) 2017-05-16 2023-07-24 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 Ｐｄ－ｌ１抗体医薬組成物およびその使用
CN111372947A (zh) 2017-10-30 2020-07-03 豪夫迈·罗氏有限公司 在体内从单特异性抗体产生多特异性抗体的方法
WO2019114839A1 (zh) 2017-12-15 2019-06-20 泰伦基国际有限公司 一种预防或治疗骨关节炎的方法和药物
SG11202008098TA (en) 2018-03-28 2020-10-29 Axon Neuroscience Se Antibody-based methods of detecting and treating alzheimer's disease
MX2020010729A (es) * 2018-04-13 2021-03-09 Genentech Inc Formulaciones de inmunoconjugado anti-cd79b estables.
US11103552B2 (en) 2018-05-10 2021-08-31 Regeneron Pharmaceuticals, Inc. High concentration VEGF receptor fusion protein containing formulations
US11519020B2 (en) 2018-05-25 2022-12-06 Regeneron Pharmaceuticals, Inc. Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
US11987629B2 (en) 2018-06-01 2024-05-21 Tayu Huaxia Biotech Medical Group Co., Ltd. Compositions and uses thereof for treating disease or condition
JP7511308B2 (ja) 2018-06-18 2024-07-05 ユーリカ セラピューティックス， インコーポレイテッド 前立腺特異的膜抗原（ｐｓｍａ）を標的とする構築物及びその使用
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
WO2020061374A1 (en) 2018-09-20 2020-03-26 Mandalmed, Inc. Methods and compositions for preventing, treating, and reversing liver fibrosis
WO2020089743A1 (en) * 2018-11-02 2020-05-07 Cadila Healthcare Limited Pharmaceutical composition of pegylated l-asparaginase
EA202191058A1 (ru) 2018-11-16 2021-10-07 Мемориал Слоун Кеттеринг Кэнсер Сентр Антитела против муцина-16 и способы их применения
GB201820554D0 (en) 2018-12-17 2019-01-30 Univ Oxford Innovation Ltd BTLA antibodies
GB201820547D0 (en) 2018-12-17 2019-01-30 Oxford Univ Innovation Modified antibodies
CN111375057B (zh) * 2018-12-28 2024-06-21 上海复宏汉霖生物技术股份有限公司 一种包含抗Her2单克隆抗体的药物配制剂
CN112121150A (zh) * 2019-06-24 2020-12-25 杭州生物医药创新研究中心 一种成纤维细胞生长因子10冻干粉
CN112300279A (zh) 2019-07-26 2021-02-02 上海复宏汉霖生物技术股份有限公司 针对抗cd73抗体和变体的方法和组合物
EP3808777A1 (en) 2019-10-16 2021-04-21 Glenmark Specialty S.A. Stable liquid antibody formulations
CN114867488A (zh) 2020-01-17 2022-08-05 泰伦基国际有限公司 一种治疗神经损伤及其相关病症的方法
CN115427066A (zh) 2020-02-06 2022-12-02 泰伦基国际有限公司 一种预防和治疗多发性硬化症的方法和药物
BR112022016491A2 (pt) 2020-02-28 2022-10-11 Shanghai Henlius Biotech Inc Construto anti-cd137 e usos do mesmo
CN115151573A (zh) 2020-02-28 2022-10-04 上海复宏汉霖生物技术股份有限公司 抗cd137构建体、多特异性抗体及其用途
KR20220158036A (ko) 2020-03-24 2022-11-29 탈렌젠 인터내셔널 리미티드 파킨슨병의 치료 방법 및 약물
EP4122489A4 (en) 2020-03-24 2023-04-12 Talengen International Limited METHOD AND MEDICINE FOR PROMOTING DEGRADATION OF A MISFOLDED PROTEIN AND OF AN AGGREGATE THEREOF
WO2021190558A1 (zh) 2020-03-24 2021-09-30 泰伦基国际有限公司 一种治疗阿尔茨海默病的方法和药物
EP4122481A4 (en) 2020-03-24 2023-04-05 Talengen International Limited METHODS AND MEDICATIONS FOR TREATMENT OF HUNTINGTON'S DISEASE
CN113993900B (zh) 2020-05-27 2023-08-04 舒泰神（北京）生物制药股份有限公司 特异性识别神经生长因子的抗体及其用途
BR112022024629A2 (pt) 2020-06-02 2023-02-23 Dynamicure Biotechnology Llc Construtos anti-cd93 e seus usos
CN116529260A (zh) 2020-06-02 2023-08-01 当康生物技术有限责任公司 抗cd93构建体及其用途
GB202008860D0 (en) 2020-06-11 2020-07-29 Univ Oxford Innovation Ltd BTLA antibodies
CA3180138A1 (en) * 2020-06-12 2021-12-16 Ichnos Sciences SA Antibody formulation diluent
CN113827717A (zh) * 2020-06-23 2021-12-24 三生国健药业（上海）股份有限公司 抗her2单克隆抗体冻干制剂及制备方法
JP2023541217A (ja) 2020-07-10 2023-09-29 シャンハイ ジェミンケア ファーマシューティカル カンパニー，リミティド 抗ＩｇＥ改変抗体及びその適用
US20230322935A1 (en) 2020-07-29 2023-10-12 Dynamicure Biotechnology Llc Anti-cd93 constructs and uses thereof
IL300415A (en) 2020-08-14 2023-04-01 Hoffmann La Roche Methods for treating multiple sclerosis with ocralizumab
CN114246944A (zh) * 2020-09-24 2022-03-29 盛禾(中国)生物制药有限公司 一种双特异性抗体的药物组合物及其用途
CN112684177B (zh) * 2020-12-17 2024-05-28 北京维德维康生物技术有限公司 一种乳品多因子快速检测试剂盒及其检测方法
WO2022187863A1 (en) 2021-03-05 2022-09-09 Dynamicure Biotechnology Llc Anti-vista constructs and uses thereof
TW202300648A (zh) 2021-03-25 2023-01-01 美商當康生物科技有限公司 抗-igfbp7構築體及其用途
WO2022266660A1 (en) 2021-06-17 2022-12-22 Amberstone Biosciences, Inc. Anti-cd3 constructs and uses thereof
WO2023283611A1 (en) 2021-07-08 2023-01-12 Staidson Biopharma Inc. Antibodies specifically recognizing tnfr2 and uses thereof
JP2024525769A (ja) 2021-07-14 2024-07-12 舒泰神（北京）生物製薬股フン有限公司 Ｃｄ４０を特異的に認識する抗体およびその使用
WO2023019556A1 (zh) * 2021-08-20 2023-02-23 齐鲁制药有限公司 一种高浓度抗her2的抗体制剂及其用途
CN116829179A (zh) 2021-12-06 2023-09-29 北京三诺佳邑生物技术有限责任公司 特异性结合肺炎克雷伯菌o2抗原和o1抗原的双特异性抗体以及组合物
WO2024020407A1 (en) 2022-07-19 2024-01-25 Staidson Biopharma Inc. Antibodies specifically recognizing b- and t-lymphocyte attenuator (btla) and uses thereof
TW202417034A (zh) 2022-08-19 2024-05-01 大陸商億一生物醫藥開發（上海）有限公司 包含ｇ—ｃｓｆ之調配物及其用途
WO2024054929A1 (en) 2022-09-07 2024-03-14 Dynamicure Biotechnology Llc Anti-vista constructs and uses thereof
CN115746082A (zh) * 2022-12-02 2023-03-07 大连工业大学 一种调控糖基化鳕鱼蛋白结构的方法及其在制备高内相乳液中的应用

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5896028A (ja) * 1981-11-30 1983-06-07 Takeda Chem Ind Ltd ヒトＩｇＥの製造法
US4482483A (en) * 1983-04-06 1984-11-13 Armour Pharmceutical Company Composition of intravenous immune globulin
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
ATE68524T1 (de) * 1985-07-09 1991-11-15 Quadrant Bioresources Ltd Beschuetzung von proteinen und aehnlichem.
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
JPH0827283B2 (ja) * 1986-03-10 1996-03-21 財団法人化学及血清療法研究所 免疫凝集反応用組成物
US4806343A (en) * 1986-03-13 1989-02-21 University Of Southwestern Louisiana Cryogenic protectant for proteins
JPS62289523A (ja) * 1986-06-09 1987-12-16 Green Cross Corp:The 静脈投与用免疫グロブリンの加熱処理方法
JP3040121B2 (ja) * 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
WO1989009402A1 (en) * 1988-03-30 1989-10-05 Toray Industries, Inc. FREEZE-DRIED COMPOSITION CONTAINING ENZYME-LABELED ANTIHUMAN INTERFERON-beta ANTIBODY AND ENZYMATIC IMMUNOASSAY KIT CONTAINING THE COMPOSITION
JPH01268645A (ja) * 1988-04-18 1989-10-26 Teijin Ltd シュワルツマン反応抑制剤
WO1989011297A1 (en) * 1988-05-27 1989-11-30 Centocor, Inc. Freeze-dried formulation for antibody products
CN1047342A (zh) * 1989-05-13 1990-11-28 杭州市中心血站 因子viii的生产及其病毒灭活方法
DE69026380T2 (de) * 1989-06-23 1996-10-17 The Liposome Co.,Inc., Princeton, N.J. Zielliposomen und verfahren zur kupplung von liposomen-proteinen
EP0479909B1 (en) 1989-06-29 1996-10-30 Medarex, Inc. Bispecific reagents for aids therapy
US5011676A (en) * 1990-03-27 1991-04-30 Thomas Jefferson University Method to directly radiolabel antibodies for diagnostic imaging and therapy
AU662311B2 (en) * 1991-02-05 1995-08-31 Novartis Ag Recombinant antibodies specific for a growth factor receptor
JPH0565233A (ja) * 1991-03-08 1993-03-19 Mitsui Toatsu Chem Inc モノクローナル抗体含有凍結乾燥製剤
JPH06507398A (ja) 1991-05-14 1994-08-25 リプリジェン　コーポレーション Ｈｉｖ感染治療のための異種複合抗体
ES2206447T3 (es) 1991-06-14 2004-05-16 Genentech, Inc. Anticuerpo humanizado para heregulina.
CA2120701A1 (en) * 1991-10-11 1993-04-15 Sharon M. Devereaux Unit-of-use reagent composition for specific binding assays
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
US5290764A (en) * 1992-01-14 1994-03-01 The Dupont Merck Pharmaceutical Company Stabilization of active plasminogen activator inhibitor-1
DE69308573T2 (de) 1992-08-17 1997-08-07 Genentech Inc Bispezifische immunoadhesine
FR2700471B1 (fr) * 1993-01-21 1995-04-07 Pasteur Merieux Serums Vacc Utilisation d'anticorps monoclonaux anti-LFA-1 pour la préparation d'un médicament destiné à prévenir le rejet des greffes d'organes solides et médicaments obtenus.
US5589167A (en) * 1993-02-23 1996-12-31 Genentech, Inc. Excipient stabilization of polypeptides treated with organic solvents
FR2708467B1 (fr) * 1993-07-30 1995-10-20 Pasteur Merieux Serums Vacc Préparations d'immunoglobulines stabilisées et procédé pour leur préparation.
DE4344824C1 (de) 1993-12-28 1995-08-31 Immuno Ag Hochkonzentriertes Immunglobulin-Präparat und Verfahren zu seiner Herstellung
FR2719479B1 (fr) * 1994-05-04 1996-07-26 Sanofi Elf Formulation stable lyophilisée comprenant une protéine: kit de dosage.
JP4142095B2 (ja) * 1994-06-02 2008-08-27 クアドラント・ドラツグ・デリバリー・リミテツド 各種物質の再水和または融解時の凝集を防止する方法及び該方法により得られる組成物
IL122910A (en) * 1995-07-27 2002-05-23 Genentech Inc Stable isotonic protein formulation that has undergone lyophilization

Also Published As

Publication number Publication date
JP2011256205A (ja) 2011-12-22
NO323557B3 (no) 2007-06-11
EP1516628B1 (en) 2013-08-21
EP2275119A1 (en) 2011-01-19
SI2275119T1 (sl) 2013-12-31
CN102416176A (zh) 2012-04-18
AU716785B2 (en) 2000-03-09
ES2434840T3 (es) 2013-12-17
DK1516628T3 (da) 2013-09-08
CN1191490A (zh) 1998-08-26
JP5043507B2 (ja) 2012-10-10
PT1516628E (pt) 2013-09-24
JP5043506B2 (ja) 2012-10-10
DK2275119T3 (da) 2013-11-11
AR074517A2 (es) 2011-01-26
AR003969A1 (es) 1998-09-30
CA2226575C (en) 2011-10-18
PT2275119E (pt) 2013-11-21
RU2013141049A (ru) 2015-03-20
JPH11510170A (ja) 1999-09-07
NO980335D0 (no) 1998-01-26
IL122910A0 (en) 1998-08-16
HK1152876A1 (en) 2012-03-16
HK1117075A1 (en) 2009-01-09
NZ313503A (en) 2000-01-28
CN100360184C (zh) 2008-01-09
EP2275119B1 (en) 2013-09-25
NO323557B1 (no) 2007-06-11
CN1151842C (zh) 2004-06-02
WO1997004801A1 (en) 1997-02-13
JP2017039778A (ja) 2017-02-23
JP2007217430A (ja) 2007-08-30
JP2011256206A (ja) 2011-12-22
EP0845997A1 (en) 1998-06-10
CA2745743A1 (en) 1997-02-13
MX9800684A (es) 1998-04-30
JP2016033156A (ja) 2016-03-10
JP2007238628A (ja) 2007-09-20
EP1516628A1 (en) 2005-03-23
NO980335L (no) 1998-03-26
CA2226575A1 (en) 1997-02-13
AU6599296A (en) 1997-02-26
IL122910A (en) 2002-05-23
ES2435462T3 (es) 2013-12-19
CN1539505A (zh) 2004-10-27
RU2497500C2 (ru) 2013-11-10
NO2007012I1 (no) 2007-11-29
NZ500539A (en) 2001-11-30
SI1516628T1 (sl) 2013-10-30

Similar Documents

Publication Publication Date Title
BR9609743A (pt) Formulação reconstituída estável método para a preparação de uma formulação artigo manufaturado e uso da formação
DE69618018T2 (de) Arzneimittel enthaltend botulinum toxin oder neurotoxin und herstellungsverfahren
CA2454587C (en) Stable lyophilized pharmaceutical formulation of igg antibodies
DE69130113D1 (de) Proteine mit geänderten epitopen und verfahren zur deren herstellung
CA2103887A1 (en) Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
DE68918867D1 (de) Mutanten des hiv-1 Hüllproteins mit fehlenden hypervariabelen domänen.
MX12880A (es) Procedimiento para la produccion de una preparacion de proteina humana, estable al almacenamiento y producto obtenido
ES2116790T3 (es) Anticuerpos monoclonales (mak) contra antigenos asociados a tumores, su preparacion y empleo.
DE69724970D1 (de) Verfahren zur behandlung von hypersensitivität typ i unter verwendung von monophosphoryl-lipid a
EP0335133A3 (en) Drug delivery using pulmonary surfactant fo facilitate absorption
NO900758L (no) Fremgangsmaate for fremstilling av hybridprotein.
DE69837159D1 (de) Verfahren zur herstellung einer einzeldosisspritze mit lyophilisierter proteinmischung zur verabreichung eines volumens von weniger als 0,5 ml
FI884240A (fi) Menetelmä paikalliseen käyttöön tarkoitetun farmaseuttisen valmisteen valmistamiseksi
JPS646220A (en) Stable freeze-dry herpes virus live vaccine
WO2002038611A3 (en) Method of producing antibodies by immunization with conjugates of molecules coupled to charge-modified proteins
KR910016347A (ko) C형 간염 바이러스에 대한 초면역 글로블린 및 이의 제조방법
JPS63225320A (ja) 抗体を含有する安定水性組成物
ATE266676T1 (de) Verwendung von aviären, vitellinen, gegen hiv- antigene gerichteten antikörpern zur herstellung pharmazeutischer zubereitungen
Ramia et al. The effect of Pseudomonas aeruginosa on the immunogenicity of enterobacterial common antigen
Nixdorff et al. Endotoxin membrane protein complexes as immunomodulators
MX169213B (es) Procedimiento para la conservacion de enzimas de membranas preferentemente citocromo oxidasa, solubles o reconstituidas mediante liofilizacion
ES2129342A1 (es) "formulacion de vacunas liposomales y su preparacion".
TH13166EX (th) สารผสมของโซมาโตโทรปินที่ถูกควบคุมให้ปล่อยออกมาและวิธีการเตรียมสารดังกล่าว
SE8400934D0 (sv) Forfarande for framstellning av lyofiliserade, adsorberade, polyvalenta vacciner

Legal Events

Date Code Title Description
EG Technical examination (opinion): publication of technical examination (opinion)
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: DE ACORDO COM O ART. 37, INDEFIRO O PRESENTE PEDIDO COM BASE NOS ART. 8O E ART. 13 DA LPI 9279/96.

B12B Appeal against refusal [chapter 12.2 patent gazette]